Loading stock data…
HCM
$13.30-0.14 (-1.04%)
Market ClosedLast close May 1
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
HUTCHMED (China) Limited in the Healthcare sector is trading at $13.30. The stock is currently near its 52-week low of $12.82, remaining 12.2% below its 200-day moving average. Technical signals show oversold RSI of 24 and bearish MACD signal, explaining why HCM maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 24) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.30
Potential Upside
362%
Whystock Fair Value$61.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$22.85+71.8%
Range$13.75 – $40.40
Fundamentals
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides F...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.50B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.49
Beta
Defensive asset. Lower volatility than the S&P 500.
0.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.91%
Volume
Today's trading volume
58,582
Recent News
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at the 30th Deutsche Bank deposit receipts virtual investor conference. 2025 financial performance and l
Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...
Despite challenges, HUTCHMED (China) Ltd (HCM) reports robust sales growth and outlines ambitious oncology revenue targets for 2026.
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday, with the State Street Health Care Select Sector
Hutchmed price target lowered to $21 from $22 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional commentary about fruquintinib indication expansion in 2026 and increasing the number of Fruzaqla markets bolsters the firm’s confidence that Hutchmed can meet their 2026 guidance for Oncology/Immunology, the analyst tells investors.Claim 70% Off TipRanks Premiu